Investopedia: Medtronic Marking Time

These aren't the glory days for med-tech giant Medtronic (NYSE: MDT ), as fiscal 2014 will be a pretty weak year from a growth perspec...

Seeking Alpha: FDA Kicks Wright Medical In The Groin - What Now?

There are days when the news that comes out of the stock market makes you want to rip the router out of the wall and just forget about stoc...

Seeking Alpha: In-Line Doesn't Cut It For NuVasive

Small-cap spine specialist NuVasive ( NUVA ) may have reported basically in-line numbers for the second quarter, but that's not helpi...

Seeking Alpha: Spectranetics Has Multiple Attractive Opportunities, But Will They Execute?

I've had a love/hate relationship with Spectranetics ( SPNC ) for more than 15 years now. I've always loved the potential of the ...

Investopedia: Abbott Labs Making Progress On Margins, Now It Needs More Growth

Since making the split from AbbVie (Nasdaq: ABBV ), Abbott Labs (NYSE: ABT ) has had something of a mixed debut. The stock has not only l...

Investopedia: Drugs Driving JNJ, With Slow Progress In Devices And Consumer

Another quarter is in the books, and not all that much has changed at healthcare giant Johnson & Johnson (NYSE: JNJ ). The company...

Investopedia: Abbott Adds Two Promising Products

Abbott Labs (NYSE: ABT ) has never been shy about using M&A to build its business, and it was generally assumed that more deals would ...

MassDevice: Diabetes: The Path To An Artificial Pancreas Looks A Little More Reasonable

There are more than a few similarities between the idea of building an artificial pancreas and finding the Holy Grail – everybody agrees t...

MassDevice: Smarter Strategic Moves Bode Well For Wright Medical

There's a saying in the markets that there's always a bull market somewhere. Along similar lines, it's almost always possible...

MassDevice: The Bulls May Have Run A Little Too Far With St. Jude Medical

Combine a bull market with increasing optimism that major med-tech markets are stabilizing, and it's not so hard to see why stocks like...

MassDevice: Can C.R. Bard Use A Windfall To Reignite Growth?

C.R. Bard (NYSE: BCR ) has a problem; specifically, a growth problem. While the company has #1 or #2 market share in markets that make up...

MassDevices: Boston Scientific May Finally Be On The Right Path Again

It feels like Boston Scientific (NYSE: BSX ) has spent the majority of the past decade in a perpetual limbo of ineffectual turnaround. Th...

MassDevice: The Strange Case Of The Diabetes Market

It wasn't so long ago when diabetes was one of the hot sectors of med-tech where many companies felt they had to have a presence, no m...

MassDevice: Can Johnson & Johnson Fire On All Cylinders Again?

In what has become a red-hot stock market for med-tech stocks, it's the rare quality company that hasn't taken part in the rally. ...

MassDevice: Edwards Lifesciences Comes Back Down To Earth ... Hard

Although I had been writing for some time that I thought Edwards Lifesciences (NYSE: EW) was significantly overvalued by the market, I do...

Investopedia: Medtronic Still Reporting Weak Growth, But A Relatively Rare Bargain

Bargains are getting harder and harder to find in the med-tech sector these days, and with Medtronic (NYSE: MDT ) sporting a double-digit E...

Investopedia: In A Growth-Starved Sector, Becton Dickinson Rules

It's a curious thing that investors' desire for short-term growth will often lead them to pay what looks like much too high a price...

Investopedia: It Gets A Little Harder From Here For Covidien

Covidien (NYSE: COV ) has been one of the strongest large-cap med-tech stories over the past year or so. At a time when companies like Johns...

Investopedia: Broad Weakness Makes It Harder To Like St. Jude Today

I've been relatively optimistic about St. Jude Medical 's (NYSE: STJ ) long-term prospects as the company navigates its current mul...

Investopedia: Pharma Is Doing All The Pulling For Johnson & Johnson

While other healthcare companies including Covidien (NYSE: COV ) and Abbott (NYSE: ABT ) have seen fit to split their drug and device busi...